In summary, the AMPK/SIRT1/PGC‐1α pathway serves as a central hub integrating multiple pathological processes in CKD (inflammation, fibrosis, and metabolic dysregulation), making it a highly promising therapeutic target. This evidence concerns the gene PRKAA2 and chronic kidney disease.